Home > Resources > Whitepapers > Econometric Analysis Of Biopharmaceutical Transfer Pricing

Econometric Analysis Of Biopharmaceutical Transfer Pricing

Interestingly, the above quote by Benjamin Franklin epitomizes in many respects the significant daily challenges faced by biopharmaceutical companies – to lengthen and improve the quality of life, while always facing the mortality of patients against increasingly challenging diseases, and at the same time engaged in pursuing this noble endeavor in a prudent economic fashion. This white paper goes outside the traditional boundaries of biopharmaceutical commercial analytics to explore a topic noted in the second part of Benjamin Franklin’s quote – taxes. In particular, this white paper will explore the application of econometric analysis of biopharmaceutical transfer pricing, a direct result of differentials in cross-country corporate income tax rates. Given disparities in the US corporate income tax rate relative to other developed countries with major biopharmaceutical operations, this is a white paper that deserves your attention, and will guarantee not to “tax” you (pun intended).

Spotlight

Aerobit Health Limited

There is a need for patients to remember to adhere with their treatments and keep doctors in the loop with critical data. Aerobit is platform of smart hardware and software making managing asthma easier and more effective than ever. Aerobit’s mission is to be at the epicenter of improving Asthma care through a revolution in digital healthcare. Aerobit is a digital health startup building an asthma care platform with a Smart Inhaler Device at the epicenter. Our aim is to improve the quality of life of millions of asthma sufferers in the UK and reduce the risk of unnecessary fatalities due to this common chronic disease.

OTHER WHITEPAPERS

Artificial Intelligence in Drug Manufacturing

whitePaper | May 25, 2023

CDER’s mission is to ensure that human drugs are safe and effective, meet established quality standards, and are available to patients. To advance this mission, FDA’s Pharmaceutical Quality for the 21st Century Initiative promotes an efficient, agile, and flexible pharmaceutical manufacturing sector that reliably produces quality drugs without excessive regulatory oversight.

Adapting to Pharma’s Next Normal

whitePaper | October 4, 2022

Let’s just say what we’re all thinking: 2020 was rough. It threw every element of our lives into disarray. We suddenly had to become experts at navigating a new way of working, schooling and socialising. It was disruptive and it was challenging, but it was also transformative

Blockchain technology in the pharmaceutical industry

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

The Ultimate Guide to Pharmaceutical Quality Managemen

whitePaper | October 20, 2022

When the first Nokia and Motorola cell phones that were affordable and small enough to fit in your pocket hit the market, they not only changed how we viewed phone technology but how we communicated.

BUILDING A TOMORROW-READY LAB

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Econometric Analysis Of Biopharmaceutical Transfer Pricing